(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 March 2012 (29.03.2012)

PCT

(10) International Publication Number
WO 2012/038463 A2

(51) International Patent Classification:
G01N 33/574 (2006.01)

(21) International Application Number:
PCT/EP2011/066397

(22) International Filing Date:
21 September 2011 (21.09.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1015765.9 21 September 2010 (21.09.2010) GB
61/384,784 21 September 2010 (21.09.2010) US

(71) Applicant *(for all designated States except US)*: **IMMATICS BIOTECHNOLOGIES GMBH** [DE/DE]; Paul-Ehrlich-Strasse 15, 72076 Tuebingen (DE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **SINGH, Harpreet** [DE/DE]; Bei den Pferdestaellen 9, 72072 Tuebingen (DE). **WALTER, Steffen** [DE/DE]; Steinenbergstrasse 2, 72764 Reutlingen (DE). **MENDRZYK, Regina** [DE/DE]; Engelbergstrasse 43d, 79106 Freiburg im Breisgau (DE). **BRONTE, Vincenzo** [IT/IT]; Department of Pathology, Immunology Section, Verona University, P.le.L.A. Scuro, 10, I-37134 Verona (IT). **MANDRUZZATO, Susanna** [IT/IT]; Istituto Oncologico Veneto, Università degli studi di Padova, Via Gattamelata 64, I-35128 Padova (IT).

(74) Agent: **KRAUSS, Jan B.**; Boehmert & Boehmert, Pettenkoferstrasse 20 - 22, 80336 Munich (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2012/038463 A2

(54) **Title**: USE OF MYELOID CELL BIOMARKERS FOR THE DIAGNOSIS OF CANCER

(57) **Abstract**: The present invention relates to the use of myeloid cell biomarkers for the differential diagnosis, prognosis, and monitoring of renal cell carcinoma (RCC) or colorectal cancer (CRC). The present invention furthermore relates to monitoring the effect of a treatment against renal cell carcinoma (RCC) or colorectal cancer (CRC), and establishing a prognosis of the outcome of the treatment of renal cell carcinoma (RCC) or colorectal cancer (CRC). The present invention furthermore relates to panels of cellular biomarkers for use in the above methods, in particular multicolor panels for measuring said biomarkers.